Peter Verheesen

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

Peter Ulrichts, Antonio Guglietta, Torsten Dreier et al. · Journal of Clinical Investigation · 2018 · 382 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial*

Matthias Goebeler, Zsuzsanna Bata‐Csörgõ, Clara De Simone et al. · British Journal of Dermatology · 2021 · 99 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear poly(A)-binding protein with a single-domain intracellular antibody

Peter Verheesen, Anna de Kluijver, Silvana van Koningsbruggen et al. · Human Molecular Genetics · 2005 · 90 citations

Life Sciences, Biochemistry, Molecular Biology +17

Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography

Peter Verheesen, Mark R. ten Haaft, Nigel Lindner et al. · Biochimica et Biophysica Acta (BBA) - General Subjects · 2003 · 73 citations

Pharmacy, Biochemistry, Immunology +17

Reliable and controllable antibody fragment selections from Camelid non-immune libraries for target validation

Peter Verheesen, Andreas Roussis, Hans J. de Haard et al. · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · 2006 · 69 citations

Pharmacy, Immunology, Antibody Engineering +14